In heart failure patients with iron deficiency (ferritin < 100 µg/L or ferritin 100‑300 µg/L with transferrin saturation < 20 %), what is the role of ferric carboxymaltose, including its indications, recommended dosing regimen, monitoring parameters, and alternative therapies?

Ferric Carboxymaltose in Heart Failure Patients

Intravenous ferric carboxymaltose (FCM) should be administered to symptomatic heart failure patients with reduced ejection fraction (LVEF ≤40-45%) and iron deficiency to improve exercise capacity, quality of life, and reduce heart failure hospitalizations. 1

Indications for FCM

Who qualifies:

• Symptomatic chronic heart failure with LVEF <40% (Class IIa recommendation, Level A evidence) 1
• Iron deficiency defined as:
  • Ferritin <100 µg/L, OR
  • Ferritin 100-300 µg/L with transferrin saturation (TSAT) <20% 1

Important caveat: The evidence base comes from trials enrolling patients with LVEF ≤45%, though guidelines specify <40%. There is no clinical evidence for FCM in HFpEF (LVEF ≥50%) and limited evidence in HFmrEF (LVEF 40-49%). 1

Dosing Regimen

For Iron Deficiency Anemia

Standard dosing (patients ≥50 kg): 750 mg IV × 2 doses separated by at least 7 days (total 1,500 mg per course) 2

Alternative single-dose: 15 mg/kg (maximum 1,000 mg) as a single dose in adults 2

For patients <50 kg: 15 mg/kg IV in two doses separated by at least 7 days 2

For Heart Failure with Iron Deficiency

The FDA-approved dosing is weight and hemoglobin-based 2:

Patients <70 kg:

• Hb <10 g/dL: 1,000 mg Day 1, then 500 mg Week 6
• Hb 10-14 g/dL: 1,000 mg Day 1 only
• Hb >14 to <15 g/dL: 500 mg Day 1 only

Patients ≥70 kg:

• Hb <10 g/dL: 1,000 mg Day 1, then 1,000 mg Week 6
• Hb 10-14 g/dL: 1,000 mg Day 1, then 500 mg Week 6
• Hb >14 to <15 g/dL: 500 mg Day 1 only

Maintenance dosing: 500 mg at 12,24, and 36 weeks if ferritin <100 ng/mL or ferritin 100-300 ng/mL with TSAT <20% 2

Critical limitation: No data exist to guide dosing beyond 36 weeks or with Hb ≥15 g/dL 2

Administration

Route options:

1. Undiluted slow IV push: 100 mg/min (15 minutes for 1,000 mg dose) 1
2. IV infusion: Dilute up to 1,000 mg in no more than 250 mL normal saline (minimum concentration 2 mg iron/mL), infuse over at least 15 minutes 2

Maximum weekly dose: 1,000 mg iron (20 mL FCM) per week 1

Post-administration monitoring: Observe patients for adverse effects for at least 30 minutes after each injection 1, 2

Monitoring Parameters

Initial assessment:

• Serum ferritin
• Transferrin saturation
• Hemoglobin level
• Body weight 1

Follow-up monitoring:

• Re-evaluate iron status at 3 months after correction dose 1
• Check ferritin and TSAT 1-2 times per year or if clinical picture changes or hemoglobin decreases 1
• Check serum phosphate levels in patients requiring repeat courses within 3 months or those at risk for hypophosphatemia 2

Important pitfall: Dosing is calculated based on body weight and hemoglobin levels, NOT ferritin or TSAT levels 1

Contraindications

Absolute contraindications:

• Hypersensitivity to FCM or its excipients 1
• Known serious hypersensitivity to other parenteral iron products 1
• Anemia not attributed to iron deficiency 1
• Evidence of iron overload or disturbances in iron utilization 1
• Hemoglobin >15 g/dL (no safety/efficacy data) 1

Stop treatment immediately:

• Ongoing bacteremia 1

Cautions

Use with extreme caution in:

• Acute or chronic infection 1
• History of severe asthma, eczema, or atopic allergies (increased hypersensitivity risk) 1
• Immune/inflammatory conditions (SLE, rheumatoid arthritis) 1
• Patients requiring repeat infusions (risk of treatment-emergent hypophosphatemia) 3

Alternative Therapies

Oral iron is NOT recommended. The IRONOUT HF trial demonstrated that oral iron minimally replenished iron stores, did not improve exercise capacity or heart failure symptoms, and is poorly tolerated with gastrointestinal side effects in up to 60% of patients. 1 No head-to-head trials compare IV iron with oral iron in heart failure, but the evidence strongly favors IV administration. 1

Other IV iron formulations: While ferric derisomaltose has shown cardiovascular mortality benefit in recent trials 3, FCM has the most extensive evidence base in heart failure with demonstrated improvements in functional capacity, symptoms, and quality of life, plus potential reductions in hospitalizations. 1

Expected Outcomes

What FCM improves:

• Exercise capacity (6-minute walk test) 1, 4
• NYHA functional class 4
• Patient-reported quality of life 1, 4
• Heart failure symptoms 1
• Reduction in recurrent heart failure hospitalizations 1, 5

What remains unproven:

• Mortality benefit (trials not powered for this endpoint) 1
• Though recent meta-analyses suggest trends toward reduced cardiovascular and all-cause mortality at 1 year 5

Common Pitfalls to Avoid

1. Do not over-dilute FCM when giving as infusion—this affects drug stability (minimum 2 mg iron/mL) 1, 2
2. Do not use if Hb >15 g/dL—no safety or efficacy data exist 1
3. Monitor for extravasation—brown discoloration can be long-lasting 2
4. Do not substitute oral iron—it is ineffective in this population 1
5. Screen for hypophosphatemia with repeat courses, especially within 3 months 2